Patents Examined by Jae W Lee
-
Patent number: 11781159Abstract: Hydroxycarboxylic acids may be biosynthesized from a carbonaceous feedstock and then isolated through forming and subsequently hydrolyzing an intermediate sophorolipid. After biosynthesizing a hydroxycarboxylic acid in a cell culture medium or otherwise providing a hydroxycarboxylic acid in a first aqueous medium, the hydroxycarboxylic acid and glucose may be converted into at least one sophorolipid by a suitable microorganism or an enzyme cocktail. The at least one sophorolipid may be then be separated from the cell culture medium or first aqueous medium and then hydrolyzed in a second aqueous medium to form the hydroxycarboxylic acid and glucose as free components separate from the cell culture medium or first aqueous medium. The hydroxycarboxylic acid is present as a phase separate from the second aqueous medium and the glucose remains in the second aqueous medium.Type: GrantFiled: October 12, 2020Date of Patent: October 10, 2023Assignee: ExxonMobil Technology and Engineering CompanyInventors: Xiaozhou Zhang, Zarath M Summers, Partha Nandi, Mark P Hagemeister, Jihad M Dakka, Mohor Chatterjee, Vera Grankina
-
Patent number: 11771745Abstract: Provided are compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.Type: GrantFiled: June 29, 2021Date of Patent: October 3, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: Jan P. Kraus, Tomas Majtan, Erez Bublil
-
Patent number: 11773385Abstract: Provided herein, in some aspects, are polypeptide monomers comprising an angiotensin-converting enzyme 2 (ACE2) ectodomain and an oligomerization domain. Also provided herein are oligomeric complexes comprising ACE2 monomers. Methods of using such to monomers and oligomeric complexes for the diagnosis, prevention, and treatment of viral infections such as the coronavirus are also provided.Type: GrantFiled: May 19, 2021Date of Patent: October 3, 2023Assignee: Children's Medical Center CorporationInventors: Bing Chen, Tianshu Xiao, Yongfei Cai, Jun Zhang
-
Patent number: 11767524Abstract: Disclosed is a product and process, wherein one adds a N-terminal Histamine-Maltose Binding Protein (“MBP”) tag to endonucleases, including restriction endonucleases like Hind III, and binds the tagged fusion protein to a solid support, preferably beads, once the enzyme has digested oligonucleotides in solution, in order to arrest further digestion. Preferred beads for binding the tagged enzyme are magnetic beads, which can easily be removed from solution by binding to a support and then removing it, or can be accumulated by magnetic attraction in a particular region. More preferred are magnetic beads bound to iminodiacetic acid or nitrilotriacetic acid.Type: GrantFiled: September 22, 2020Date of Patent: September 26, 2023Assignee: ABclonal Science, Inc.Inventors: Zhenyu Zhu, Dapeng Sun, Michaela Shottes
-
Patent number: 11767525Abstract: Provided are a genome editing system CRISPR-C2c1 for site-specific modification of target sequences in a cell genome and the use thereof, wherein the system comprises a C2c1 protein or variants thereof and a guide RNA. Also provided are a method for site-specific modification of target sequences in a cell genome using the genome editing system CRISPR-C2c1, and a pharmaceutical composition comprising the genome editing system CRISPR-C2c1.Type: GrantFiled: December 27, 2017Date of Patent: September 26, 2023Assignee: Institute of Zoology, Chinese Academy of SciencesInventors: Wei Li, Qi Zhou, Fei Teng
-
Patent number: 11767546Abstract: The present invention relates to an enzyme-catalyzed process for producing UDP-N-acetyl-?-D-glucosamine (UDP-GlcNAc) from low-cost substrates uridine monophosphate and N-acetyl-D glucosamine in a single reaction mixture with immobilized or preferably co-immobilized enzymes. Uridine may be used as starting material instead of uridine monophosphate as well. Further, the process may be adapted to produce GlcNAcylated molecules and biomolecules including saccharides, particularly human milk oligosaccharides (HMO), proteins, peptides, glycoproteins, particularly antibodies, or glycopeptides, and bioconjugates, particularly carbohydrate conjugate vaccines and antibody-drug conjugates.Type: GrantFiled: September 30, 2020Date of Patent: September 26, 2023Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Reza Mahour, Thomas F. T. Rexer
-
Patent number: 11753670Abstract: Disclosed are compositions, methods, and kits for performing cell-free RNA transcription and/or cell-free protein synthesis (CFPS). The disclosed compositions, methods, and kits include or utilize components prepared from Yersinia pestis species such as cellular extracts from Yersinia pestis.Type: GrantFiled: July 12, 2022Date of Patent: September 12, 2023Assignee: The United States of America as Represented by the Secretary of the ArmyInventors: Aleksandr E. Miklos, Katherine A. Rhea, Nathan D. McDonald, Stephanie D. Cole, Patricia E. Buckley
-
Patent number: 11739358Abstract: The present invention relates to an enzyme-catalyzed process for producing UDP-galactose from low-cost substrates uridine monophosphate and D-galactose in a single reaction mixture. The process can be operated (semi)continuously or in batch mode. The process can be extended to uridine as starting material instead of uridine monophosphate. Further, the process can be adapted to produce galactosylated molecules and biomolecules including saccharides, proteins, peptides, glycoproteins or glycopeptides, particularly human milk oligosaccharides (HMO) and (monoclonal) antibodies.Type: GrantFiled: September 30, 2020Date of Patent: August 29, 2023Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Reza Mahour, Thomas F. T. Rexer
-
Patent number: 11738056Abstract: Provided herein are methods and compositions comprising a bacterium or a metabolite thereof for enhancing mitochondrial and/or peroxisomal function.Type: GrantFiled: March 9, 2021Date of Patent: August 29, 2023Assignee: THE GENERAL HOSPITAL CORPORATIONInventors: Gary Ruvkun, J. Amaranath Govindan, Elamparithi Jayamani
-
Patent number: 11739032Abstract: Disclosed herein are methods of increasing nitrogen fixation in a non-leguminous plant. The methods can comprise exposing the plant to a plurality of bacteria. Each member of the plurality comprises one or more genetic variations introduced into one or more genes or non-coding polynucleotides of the bacteria's nitrogen fixation or assimilation genetic regulatory network, such that the bacteria are capable of fixing atmospheric nitrogen in the presence of exogenous nitrogen. The bacteria are not intergeneric microorganisms. Additionally, the bacteria, in planta, produce 1% or more of the fixed nitrogen in the plant.Type: GrantFiled: January 13, 2021Date of Patent: August 29, 2023Assignee: Pivot Bio, Inc.Inventors: Karsten Temme, Alvin Tamsir, Sarah Bloch, Rosemary Clark, Emily Tung
-
Patent number: 11739336Abstract: Provided are mutants PHY1, PHY4 and PHY5 of a wild-type phytase APPA. After being treated for 10 min at 80° C., the residual enzyme activities of the mutants PHY1, PHY4 and PHY5 are respectively higher by 33.85%, 53.11% and 75.86% compared with that of APPA-M; after being treated for 5 min at 85° C., the residual enzyme activities of the mutants PHY1, PHY4 and PHY5 are respectively higher by 14.89%, 28.45% and 44.94% compared with that of APPA-M, and the heat resistance of these mutants is significantly higher than that of APPA-M.Type: GrantFiled: July 28, 2021Date of Patent: August 29, 2023Assignee: Qingdao Vland Biotech Group Co., Ltd.Inventors: Xiuxiu Wu, Huaming Wang
-
Patent number: 11732274Abstract: The instant specification provides for evolved base editors which overcome deficiencies of those in art (including increased efficiency and/or decreased requirement for specific sequence-context at an editing site) and which are obtained a result of a phage-assisted continuous evolution (PACE) system. In particular, the instant specification provides for evolved cytidine base editors (e.g., based on APOBEC1, CDA, or AID cytidine deaminase domains) which overcome deficiencies of those in art (including increased efficiency and/or decreased requirement for specific sequence-context at an editing site) and which are obtained a result of a phage-assisted continuous evolution (PACE) system.Type: GrantFiled: July 27, 2018Date of Patent: August 22, 2023Assignees: President and Fellows of Harvard College, The Broad Institute, Inc.Inventors: David R. Liu, Ben Thuronyi, Christopher Gerard Wilson
-
Patent number: 11730730Abstract: Provided herein are small molecule-inhibitors of site-specific O-glycosylation and the identification of such using cell-based fluorescent biosensors. Also provided herein are methods of treating kidney disease and cancer, such as breast cancer.Type: GrantFiled: May 26, 2021Date of Patent: August 22, 2023Assignee: Carnegie Mellon UniversityInventors: Adam D. Linstedt, Lina Song, Collin Bachert
-
Patent number: 11725196Abstract: The present disclosure relates to compositions, kits, and methods of making RNA vaccines having an appropriate cap structure. Systems, apparatus, compositions, and/or methods may include and/or use, in some embodiments, non-naturally occurring single-chain RNA capping enzymes. In some embodiments, an RNA capping enzyme may include an FCE variant having (a) an amino acid sequence at least 90% identical to positions 1 to 878 of SEQ ID NO: 1, and/or (b) one or more substitutions relative to SEQ ID NO: 1 at a position selected from positions corresponding to positions 215, 337, 572, 648, and 833 (e.g., a position selected from positions corresponding to position 215, 337, and 572) of SEQ ID NO: 1.Type: GrantFiled: July 16, 2021Date of Patent: August 15, 2023Assignee: New England Biolabs, Inc.Inventors: Mehul Ganatra, Siu-hong Chan, Christopher H. Taron, G. B. Robb
-
Patent number: 11713453Abstract: The invention concerns fusion proteins, wherein two endoglycosidases are fused, possibly via a linker. The fusion enzymes according to the invention have structure (1): EndoX-(L)p-EndoY (1), wherein EndoX is an endoglycosidase, EndoY is an endoglycosidase distinct from EndoX, L is a linker and p is 0 or 1. Such fusion enzymes capable of trimming glycoproteins comprising at least two distinct glycoforms in a single step. The invention further concerns the use of the fusion enzyme according to the invention for trimming glycoproteins. In another aspect, the invention relates to the process of production of the fusion enzyme. In a further aspect, the inventions concerns a process for trimming glycoproteins, comprising trimming the glycoprotein with a fusion enzyme according to the invention, to obtain a trimmed glycoprotein.Type: GrantFiled: December 7, 2020Date of Patent: August 1, 2023Assignee: SYNAFFIX B.V.Inventors: Remon Van Geel, Maria Antonia Wijdeven, Inge Catharina Josephina Hurkmans, Floris Louis Van Delft, Sander Sebastiaan Van Berkel
-
Patent number: 11702644Abstract: Disclosed herein include methods and compositions for incorporating an effector gene into the genome of a cell. The method can comprise introducing into a cell a donor nucleic acid comprising a recognition site, a splice acceptor site, a self-cleaving peptide sequence, an effector gene, and an optional transcript stabilization element. The donor nucleic acid can be incorporated into the intron of a target gene differentially expressed in a unique cell type and/or in a cell during a unique cell state via non-homologous end joining (NHEJ)-dependent DNA repair. There are also provided, in some embodiments, methods and compositions for treating a disease or disorder in a subject.Type: GrantFiled: April 9, 2020Date of Patent: July 18, 2023Assignee: California Institute of TechnologyInventors: Yuki Oka, Allan-Hermann Pool
-
Patent number: 11702643Abstract: The invention relates to the field of genetic engineering. In particular, the present invention relates to a novel eukaryotic genome editing system and method. More specifically, the present invention relates to a CRISPR-Cpf1 system capable of efficiently editing a genome of a eukaryotic cell and the use thereof.Type: GrantFiled: April 10, 2018Date of Patent: July 18, 2023Assignee: INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCESInventors: Wei Li, Qi Zhou, Fei Teng
-
Patent number: 11702686Abstract: The present disclosure describes compositions of matter comprising a ribonucleoprotein complex comprising a nucleic acid-guided nuclease and a guide RNA, and further comprising and a blocking nucleic acid molecule represented by Formula I, wherein Formula I in the 5?-to-3? direction comprises: A-(B-L)J-C-M-T-D; wherein A is 0-15 nucleotides in length; B is 4-12 nucleotides in length; L is 3-25 nucleotides in length; J is an integer between 1 and 10; C is 4-15 nucleotides in length; M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L)J-C and T-D are separate nucleic acid strands; T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A; and wherein the blocking nucleic acid molecule comprises a sequence complementary to a gRNA.Type: GrantFiled: February 6, 2023Date of Patent: July 18, 2023Assignees: LabSimply, Inc., The Board of Trustees of the University of IllinoisInventors: Anurup Ganguli, Ariana Mostafa, Jacob Berger, Ashish Pandey, Rashid Bashir
-
Patent number: 11692205Abstract: Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.Type: GrantFiled: May 27, 2021Date of Patent: July 4, 2023Assignee: EDITAS MEDICINE, INC.Inventors: Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg
-
Patent number: 11692188Abstract: The technical field of enzyme immobilization, and particularly, an organic-inorganic hybrid nanoflower and a preparation method thereof. The organic-inorganic hybrid nanoflower is a flower-like immobilized enzyme formed by self-assembly of a layered rare earth compound as an inorganic carrier and a biological enzyme as an organic component. The layered rare earth compound is Ln2(OH)5NO3·nH2O, where Ln is one or more of La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, or Y, and n=1.1-2.5. The biological enzyme is one or more of ?-amylase, horseradish peroxidase, or laccase. A layered rare earth compound is used as the inorganic carrier for the organic biological enzyme to form the flower-like immobilized enzyme. The immobilized enzyme has better stability and higher catalytic performance when compared with a free enzyme.Type: GrantFiled: October 9, 2021Date of Patent: July 4, 2023Assignee: Guilin University of TechnologyInventors: Xiaoli Wu, Ke Ren, Mengwu Wang, Zewen He, Shaoling Peng, Jichan Ning, Yuanli Liu